Endocytotic Albumin Uptake Pathways in Human Adipose Stem Cells and Connection to Intracellular Calcium Oscillations and the Neonatal Fc receptor.
Morshed MT., Bernhardt A., Wartenberg M., Sauer H.
Prospective Study, published in Cells Tissues Organs (2026) — summary generated from the PubMed abstract.
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Cells Tissues Organs (2026)
- Country
- Switzerland
- Reported sample size
- —
- PMID
- 40239638
- DOI
- 10.1159/000545773
Abstract (original English)
<p>Introduction: Intracellular Ca2+ oscillations of unknown function occur in human adipose tissue stem cells (ASCs). In the present study, we investigated whether Ca2+ oscillations in ASCs from subcutaneous fat tissue derived from female patients were driving albumin endocytosis by involving the neonatal Fc receptor (FcRn), which is mediating the recycling of albumin and IgG. Intracellular Ca2+ oscillations were monitored by Fluo-4 microfluorometry. Uptake of fluorescence-labeled albumin was assessed by confocal laser scanning microscopy in the presence of endocytotic pathway inhibitors. FcRn was inactivated either by use of the antagonizing antibody nipocalimab or siRNA technology. Endocytosis of albumin occurred by macropinocytosis (inhibition by cytochalasin D, wortmannin, and ethylisopropylamiloride [EIPA]), caveolae-dependent (inhibition by genistein and nystatin) and clathrin-mediated (inhibition by Dyngo-4a) pathways. In serum-free medium, Ca2+ oscillations were absent, but were induced by the addition of either fetal bovine serum, albumin, IgG or a stimulating antibody against FcRn. Consequently, FcRn expression was demonstrated in ASCs by Western blot analysis and immunohistochemistry, and colocalized with endocytosed albumin. Ca2+ oscillations were inhibited by the Ca2+ chelating agent BAPTA, the store-operated Ca2+ entry inhibitor SKF96365, the Ca2+-sensing receptor
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples, often without a control group.
How we grade evidence